3sbio - Search News

Order byBest matchMost fresh

News

Pfizer Strikes Deal With China's 3SBio

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Continue reading

· 1d · on MSN

· 1d · on MSN

Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion

· 1d · on MSN

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

1d

Pfizer Thinks Bigger With 3SBio Deal

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Fierce Biotech1d

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

1d

Stock Movers: Home Depot, 3SBio-Pfizer, UNH

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pfizer Puts $6B on the Line for 3SBio’s PD-1/VEGF Antibody

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

HKD525M Southbound Trading Net Inflow to POP MART

There was HKD525 million, HKD448.3 million and HKD401.1 million Southbound Trading net inflow to POP MART (09992.HK), BABA-W ...

Explore more

Results that may be inaccessible to you are currently showing.

Hide inaccessible results